期刊
CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS
卷 8, 期 -, 页码 127-140出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/CPAA.S100759
关键词
high-throughput screening; drug repositioning; personalized medicine; precision medicine; potentiators; correctors
资金
- European Commission [H2020-PHC-13-2014, 633545]
- H2020 Societal Challenges Programme [633545] Funding Source: H2020 Societal Challenges Programme
Mutations of the CFTR gene cause cystic fibrosis (CF), the most common recessive monogenic disease worldwide. These mutations alter the synthesis, processing, function, or half-life of CFTR, the main chloride channel expressed in the apical membrane of epithelial cells in the airway, intestine, pancreas, and reproductive tract. Lung disease is the most critical manifestation of CF. It is characterized by airway obstruction, infection, and inflammation that lead to fatal tissue destruction. In spite of great advances in early and multidisciplinary medical care, and in our understanding of the pathophysiology, CF is still considerably reducing the life expectancy of patients. This review highlights the current development in pharmacological modulators of CFTR, which aim at rescuing the expression and/or function of mutated CFTR. While only Kalydeco (R) and Orkambi (R) are currently available to patients, many other families of CFTR modulators are undergoing preclinical and clinical investigations. Drug repositioning and personalized medicine are particularly detailed in this review as they represent the most promising strategies for restoring CFTR function in CF.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据